Nicole Ullrich, MD, PhD

Publications powered by Harvard Catalyst Profiles

1. REiNS: Recommendations for Social Skills Endpoints for Clinical Trials in Neurofibromatosis Type 1. Neurology. 2021 Jul 06. View abstract
2. Long-term neurocognitive and quality of life outcomes in survivors of pediatric hematopoietic cell transplant. J Cancer Surviv. 2021 Jun 04. View abstract
3. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 May 19. View abstract
4. Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact. J Clin Oncol. 2021 Jun 01; 39(16):1752-1765. View abstract
5. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021 05; 22(5):e196-e206. View abstract
6. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 Aug; 68(8):e28930. View abstract
7. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61. View abstract
8. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021 01; 27(1):165-173. View abstract
9. Are Some Randomized Clinical Trials Impossible? J Pediatr Orthop. 2021 Jan; 41(1):e90-e93. View abstract
10. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. Pediatr Blood Cancer. 2021 Apr; 68(4):e28833. View abstract
11. Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. J AAPOS. 2020 12; 24(6):349.e1-349.e5. View abstract
12. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020 10 14; 22(10):1527-1535. View abstract
13. Neuro-Oncology Training for the Child Neurology Resident. J Child Neurol. 2021 01; 36(1):79-82. View abstract
14. Novel predictive scoring system for morbid hypothalamic obesity in patients with pediatric craniopharyngioma. Childs Nerv Syst. 2021 02; 37(2):403-410. View abstract
15. Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. Pediatr Blood Cancer. 2020 11; 67(11):e28647. View abstract
16. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View abstract
17. Prescription Psychoactive Medication Use in Adolescent Survivors of Childhood Cancer and Association With Adult Functional Outcomes. JNCI Cancer Spectr. 2020 Oct; 4(5):pkaa057. View abstract
18. Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. Genet Med. 2020 11; 22(11):1794-1802. View abstract
19. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 07; 25(7):e1109-e1116. View abstract
20. Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes (Basel). 2020 04 02; 11(4). View abstract
21. Natural History and Management of Incidentally Discovered Focal Brain Lesions Indeterminate for Tumor in Children. Neurosurgery. 2020 03 01; 86(3):357-365. View abstract
22. Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1. Ann Clin Transl Neurol. 2020 02; 7(2):245-249. View abstract
23. Optimizing Postoperative Surveillance of Pediatric Low-Grade Glioma Using Tumor Behavior Patterns. Neurosurgery. 2020 02 01; 86(2):288-297. View abstract
24. Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. J Atten Disord. 2021 06; 25(8):1177-1186. View abstract
25. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. Ann Clin Transl Neurol. 2019 12; 6(12):2555-2565. View abstract
26. Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2020 01; 41(1):299-315. View abstract
27. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454. View abstract
28. The Impact of Intraoperative Electrocorticography on Seizure Outcome After Resection of Pediatric Brain Tumors: A Cohort Study. Neurosurgery. 2019 09 01; 85(3):375-383. View abstract
29. Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. Childs Nerv Syst. 2020 02; 36(2):291-296. View abstract
30. Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics. 2019 05; 143(5). View abstract
31. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Am J Med Genet A. 2019 06; 179(6):1098-1106. View abstract
32. A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. Pediatr Neurol. 2019 12; 101:2-10. View abstract
33. Correction: Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 03; 21(3):764-765. View abstract
34. Pain affect disrupted in children with posterior cerebellar tumor resection. Ann Clin Transl Neurol. 2019 02; 6(2):344-354. View abstract
35. Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatr Blood Cancer. 2019 04; 66(4):e27584. View abstract
36. Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 01; 66(1):e27471. View abstract
37. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2019 04; 21(4):867-876. View abstract
38. Peripheral neuropathy in children and adolescents treated for cancer. Lancet Child Adolesc Health. 2018 10; 2(10):744-754. View abstract
39. The management of childhood cancer survivors at risk for stroke: A Delphi survey of regional experts. Pediatr Blood Cancer. 2018 12; 65(12):e27394. View abstract
40. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. . 2018 05; 176(5):1258-1269. View abstract
41. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis Type 1. J Pediatr Oncol Nurs. 2018 Jul/Aug; 35(4):276-286. View abstract
42. Children's at Home: Pilot Study Assessing Dedicated Social Media for Parents of Adolescents with Neurofibromatosis Type 1. J Genet Couns. 2018 04; 27(2):505-517. View abstract
43. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018 01 10; 20(1):132-142. View abstract
44. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018 01 04; 102(1):69-87. View abstract
45. Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer. 2018 03 15; 124(6):1188-1196. View abstract
46. School liaison program supporting children with neurofibromatosis type 1: a model of care for children with chronic disease. Genet Med. 2018 07; 20(7):785-788. View abstract
47. Liver Failure as the Presentation of Ornithine Transcarbamylase Deficiency in a 13-Month-Old Female. JIMD Rep. 2018; 40:17-22. View abstract
48. Visual and ocular motor outcomes in children with posterior fossa tumors. J AAPOS. 2017 Oct; 21(5):375-379. View abstract
49. Brain tumors and epileptic spasms: Natural history and outcomes. Epilepsy Behav. 2017 10; 75:25-28. View abstract
50. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View abstract
51. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2017 05 01; 19(5):689-698. View abstract
52. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A. 2017 Jun; 173(6):1714-1721. View abstract
53. A 15-Month-Old Girl Presenting With Clitoromegaly and a Chest Mass. Semin Pediatr Neurol. 2018 07; 26:128-131. View abstract
54. A 15-Year-Old Girl With Sudden Onsent Reversible Neurologic Symptoms After Cranial Irradiation for Medulloblastoma. Semin Pediatr Neurol. 2018 07; 26:124-127. View abstract
55. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017 02 01; 19(2):289-297. View abstract
56. Analysis of copy number variants in 11 pairs of monozygotic twins with neurofibromatosis type 1. . 2017 Mar; 173(3):647-653. View abstract
57. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016 Dec 13; 87(24):2575-2584. View abstract
58. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016 Aug 16; 87(7 Suppl 1):S21-30. View abstract
59. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12; 134(2):114-25. View abstract
60. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016 08; 129(1):173-8. View abstract
61. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View abstract
62. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174. View abstract
63. MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanoma. Pigment Cell Melanoma Res. 2015 Nov; 28(6):736-40. View abstract
64. CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. Front Oncol. 2015; 5:234. View abstract
65. Neurocutaneous Syndromes and Brain Tumors. J Child Neurol. 2016 10; 31(12):1399-411. View abstract
66. Bacillus cereus Cerebral Abscess During Induction Chemotherapy for Childhood Acute Leukemia. J Pediatr Hematol Oncol. 2015 Oct; 37(7):568-9. View abstract
67. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015 Oct; 56(10):1599-604. View abstract
68. Risk of seizures in children with tectal gliomas. Epilepsia. 2015 Sep; 56(9):e139-42. View abstract
69. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Res. 2015 May 01; 75(9):1897-907. View abstract
70. Hutchinson-Gilford progeria syndrome. Handb Clin Neurol. 2015; 132:249-64. View abstract
71. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603. View abstract
72. Update from the 2013 International Neurofibromatosis Conference. . 2014 Dec; 164A(12):2969-78. View abstract
73. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst. 2014 Aug; 106(8). View abstract
74. Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr. 2014 Oct; 14(4):356-64. View abstract
75. Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol. 2014 May; 75(5):799-800. View abstract
76. Cerebellar mutism after posterior fossa tumor resection: case discussion and recommendations for psychoeducational intervention. J Pediatr Oncol Nurs. 2014 Mar-Apr; 31(2):78-83. View abstract
77. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View abstract
78. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. . 2014 Mar; 164A(3):563-78. View abstract
79. Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S15-24. View abstract
80. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology. 2013 Jul 30; 81(5):427-30. View abstract
81. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5. View abstract
82. Calvarial defects and skeletal dysplasia in patients with neurofibromatosis Type 1. J Neurosurg Pediatr. 2013 Apr; 11(4):410-6. View abstract
83. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr. 2013 Apr; 11(4):417-25. View abstract
84. Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care. Pediatr Blood Cancer. 2013 Jun; 60(6):1027-30. View abstract
85. Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Cancer Surviv. 2013 Mar; 7(1):104-14. View abstract
86. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2013 May; 34(5):1091-7. View abstract
87. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16666-71. View abstract
88. Academic women faculty: are they finding the mentoring they need? J Womens Health (Larchmt). 2012 Nov; 21(11):1201-8. View abstract
89. Morning glory disc anomaly in association with ipsilateral optic nerve glioma. Arch Ophthalmol. 2012 Aug; 130(8):1082-3. View abstract
90. 168 Moyamoya Syndrome Associated with Neurofibromatosis Type 1 in Children. Neurosurgery. 2012 Aug 01; 71(2):E566. View abstract
91. Psychoactive medication use and neurocognitive function in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor study. Pediatr Blood Cancer. 2013 Mar; 60(3):486-93. View abstract
92. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View abstract
93. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun; 14(6):790-7. View abstract
94. Craniofacial abnormalities in Hutchinson-Gilford progeria syndrome. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1512-8. View abstract
95. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation. J Neurooncol. 2012 Jul; 108(3):469-75. View abstract
96. Introduction. Neurologic sequelae of cancer in children. Semin Pediatr Neurol. 2012 Mar; 19(1):1-2. View abstract
97. Neurocognitive dysfunction in survivors of childhood brain tumors. Semin Pediatr Neurol. 2012 Mar; 19(1):35-42. View abstract
98. Discovery of asymptomatic moyamoya arteriopathy in pediatric syndromic populations: radiographic and clinical progression. Neurosurg Focus. 2011 Dec; 31(6):E6. View abstract
99. Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol. 2011 Jun; 18(2):120-2. View abstract
100. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1120-6. View abstract
101. Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1. J Child Neurol. 2011 Feb; 26(2):228-30. View abstract
102. Germinoma with malignant transformation to nongerminomatous germ cell tumor. J Neurosurg Pediatr. 2010 Sep; 6(3):295-8. View abstract
103. Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer. 2010 Jul 01; 54(7):890-6. View abstract
104. Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1. J Child Neurol. 2010 Oct; 25(10):1195-202. View abstract
105. Neurologic sequelae of brain tumors in children. J Child Neurol. 2009 Nov; 24(11):1446-54. View abstract
106. Algal lipid bodies: stress induction, purification, and biochemical characterization in wild-type and starchless Chlamydomonas reinhardtii. Eukaryot Cell. 2009 Dec; 8(12):1856-68. View abstract
107. Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. Pediatr Blood Cancer. 2009 Sep; 53(3):417-23. View abstract
108. A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatr Blood Cancer. 2009 Sep; 53(3):343-7. View abstract
109. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20; 27(3):385-9. View abstract
110. CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri. Pediatr Neurol. 2008 Nov; 39(5):355-7. View abstract
111. Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol. 2008 Aug; 89(1):89-95. View abstract
112. Gender differences in research grant applications and funding outcomes for medical school faculty. J Womens Health (Larchmt). 2008 Mar; 17(2):207-14. View abstract
113. "The choking game": self-induced hypoxia presenting as recurrent seizurelike events. Epilepsy Behav. 2008 Apr; 12(3):486-8. View abstract
114. Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer. Dev Disabil Res Rev. 2008; 14(3):229-37. View abstract
115. Brainstem lesions in neurofibromatosis type 1. Neurosurgery. 2007 Oct; 61(4):762-6; discussion 766-7. View abstract
116. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View abstract
117. Extracranial metastases of glioblastoma in a child: case report and review of the literature. J Pediatr Hematol Oncol. 2007 Mar; 29(3):190-4. View abstract
118. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006 Nov; 8(6):423-9. View abstract
119. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007 Mar; 82(1):95-101. View abstract
120. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View abstract
121. Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist. 2005 Jan; 11(1):55-60. View abstract
122. Electroencephalographic correlate of juvenile Huntington's disease. J Child Neurol. 2004 Jul; 19(7):541-3. View abstract
123. Research during pediatric residency: predictors and resident-determined influences. Acad Med. 2003 Dec; 78(12):1253-8. View abstract
124. Pediatric brain tumors. Neurol Clin. 2003 Nov; 21(4):897-913. View abstract
125. Transient global amnesia in a young adult with cyanotic heart disease. Pediatr Neurol. 2003 Oct; 29(4):334-6. View abstract
126. Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience. 1998 Apr; 83(4):1161-73. View abstract
127. Cell cycle-dependent expression of a glioma-specific chloride current: proposed link to cytoskeletal changes. Am J Physiol. 1997 10; 273(4):C1290-7. View abstract
128. Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells. Am J Physiol. 1996 May; 270(5 Pt 1):C1511-21. View abstract
129. Human astrocytoma cells express a unique chloride current. Neuroreport. 1996 Apr 10; 7(5):1020-4. View abstract
130. Human astrocytoma cells express a unique chloride current. Neuroreport. 1995 Dec 29; 7(1):343-7. View abstract
131. Astrocyte Na+ channels are required for maintenance of Na+/K(+)-ATPase activity. J Neurosci. 1994 May; 14(5 Pt 1):2464-75. View abstract